About MPM BioImpact
MPM BioImpact is a venture capital firm founded in 1996. It is primarily based out of Boston, United States. As of Apr 2026, MPM BioImpact is an active investor, having invested in 9 companies, with 3 new investments in the last 12 months. It primarily invests in Series C round in United States based startups. Its investments are spread across a wide range of sectors from Life Sciences to Enterprise Applications and Consumer. Most recently it participated in the $***** Post IPO round of Adlai Nortye Overall, MPM BioImpact portfolio has seen 2 IPOs and 3 acquisitions including key companies like Radius Health, Reunion Neuroscience and Adlai Nortye. A lot of funds co-invest with MPM BioImpact, with names like Novo Holdings sharing a substantial percentage of its portfolio. MPM BioImpact has team of 25 people including 14 partners.Key Metrics
Team Members
Portfolio Count
Portfolio Sectors
Portfolio Locations
Rounds of Entry
Series B, Series A & 2 more
Portfolio IPOs
Portfolio Acquisitions
Portfolio Soonicorns
Deals in last 12 months
MPM BioImpact's List of Top Investments
MPM BioImpact has a portfolio of 9 companies. Their most notable investments are in Reunion Neuroscience and Ashibio.Their portfolio spans across United States, Canada and China. They have invested in Life Sciences, Enterprise Applications, Consumer and 1 other sectors, across stages such as Series B, Series A and 2 more. Here is the list of top investments by MPM BioImpact:Biopharmaceutical company focused on bone health and related therapeutic areas. It develops and commercializes therapies for underserved patient populations. The company's portfolio includes products for osteoporosis. It seeks partnership opportunities to expand its business and improve patient lives. The company is dedicated to scientific innovation and transformative solutions to address unmet medical needs and improve patient outcomes.
Key facts about Radius Health
- Founded Year: 2003
- Location: Boston (United States)
- Annual Revenue: $100M - $500M as on Dec 31, 2021
- Last Known Valuation: $*****
- Stage: Acquired
- Total Funding till date: $213M
- Employee Count: 257 as on May 31, 2026
- Investors: Saints Capital, Brookside Capital and 14 Others
- Latest Funding Round: Post IPO, 2022, $*****
- Highlight: Acquired
Developer of therapeutics for mental health conditions. The company's product include RE-104 serotonergic psychedelic formulated as a serotonin-2A agonist prodrug for treatment-resistant depression and postpartum depression. also, developing RE-200 series drugs that have selective and specific serotonergic psychedelic candidates.
Key facts about Reunion Neuroscience
- Founded Year: 2022
- Location: Toronto (Canada)
- Stage: Acquired
- Total Funding till date: $120M
- Investors: Novo Holdings, Palo Santo and 6 Others
- Latest Funding Round: Series A, Jan 12, 2024, $*****
- Highlight: Acquired
3. Adlai Nortye
Developer of immune oncolytic therapies for treating cancer. The company's lead product, REOLYSIN is used for treating breast cancer. It selectively lyses tumors and activates the innate and adaptive immune systems. Other candidates of the company include AN0025 (for solid tumors), AN0015 & AN3005 (for multiple tumors).
Key facts about Adlai Nortye
- Founded Year: 2014
- Location: Hangzhou (China)
- Stage: Public
- Total Funding till date: $253M
- Employee Count: 63 as on May 31, 2026
- Investors: Perceptive Advisors, Soleus Capital and 20 Others
- Latest Funding Round: Post IPO, Apr 16, 2026, $*****
- Highlight: Public
4. Crossbow
Developer of antibody therapies for cancer treatment. The company is advancing the development of novel therapies that potently target peptide-loaded major histocompatibility complexes (pMHCs) on cancer cells, using antibodies that mimic T-cell receptors (TCR-mimetics).
Key facts about Crossbow
- Founded Year: 2021
- Location: Cambridge (United States)
- Stage: Series B
- Total Funding till date: $187M
- Investors: BVF Partners, Pfizer and 12 Others
- Latest Funding Round: Series B, Mar 18, 2026, $*****
- Highlight: Editors' Pick
Long-term Swedish investment firm developing industrial and service companies. They partner with small to medium-sized businesses, fostering growth while preserving their unique culture and autonomy. They focus on niche market leaders with strong market positions and barriers to entry. Their approach emphasizes stability, predictability, and employee ownership. They invest in diverse sectors, ensuring resilience against market fluctuations. They provide financial and personnel resources to support the success of their portfolio companies. They seek businesses with strong leadership and a commitment to long-term value creation. They are a permanent owner, not seeking short-term gains. They support industrial maintenance, manufacturing, and niche service providers. They focus on B2B businesses.
Key facts about Idun Pharmaceuticals
- Founded Year: 1993
- Location: San Diego (United States)
- Stage: Public
- Total Funding till date: $53.7M
- Employee Count: 1 as on May 31, 2026
- Investors: Venrock, RBC Capital Markets and 14 Others
- Latest Funding Round: Series B, Jul 10, 2015, $*****
- Highlight: Public
MPM BioImpact's Year-on-Year Investment Trends
MPM BioImpact has invested in 9 companies over the last 25 years, with an average of 1 new investment annually in the last 10 years. In 2025, it made 1 investment, while as of Apr 2026, it has made 2 investments in this year. Its most recent first time investment was in Adlai Nortye and most recent follow-on round was in Radius Health.Year | No. of Investments | ||
|---|---|---|---|
1st Round | Follow-on | Total | |
2026 (YTD) | 2 | 0 | 2 |
2025 | 1 | 0 | 1 |
2024 | 2 | 0 | 2 |
MPM BioImpact's Investments by Stage
MPM BioImpact has made 4 investments in Series B stage with an average round size of $61.5M, 2 investments in Series A stage with an average round size of $79.9M, 2 investments in Series C stage with an average round size of $59.2M and 1 investment in Post IPO stage with an average round size of $150M.Stage of entry | No. of Investments |
|---|---|
Series B | 4 |
Series A | 2 |
Series C | 2 |
Post IPO | 1 |
Note: We have considered here, only first round of investments
MPM BioImpact's Investments by Sector
MPM BioImpact has a diverse portfolio, with companies operating in the Life Sciences, Blockchain - Industry Applications, Consumer, Enterprise Applications and Healthcare. Notably, it has invested in 7 Enterprise (B2B) companies, 7 Tech companies, 1 Blockchain company and 1 company focusing on Software.Sector | No. of Investments |
|---|---|
Life Sciences | 8 |
Blockchain - Industry Applications | 1 |
Consumer | 1 |
Enterprise Applications | 1 |
Healthcare | 1 |
Note: We have considered here, only first round of investments
MPM BioImpact's Investments by Geography
MPM BioImpact has made most investments in United States (7), followed by Canada where it has made 1 investment.Country | No. of Investments |
|---|---|
United States | 7 |
Canada | 1 |
China | 1 |
Note: We have considered here, only first round of investments
MPM BioImpact's recent investments
MPM BioImpact has made 2 investments in 2026 so far - Adlai Nortye and Crossbow.Here are the most recent investments by MPM BioImpact:
Filter this listDate | Company | Location | Round Details | Round Amount | Co-Investors |
|---|---|---|---|---|---|
Apr 16, 2026 | China | Post IPO | 1496 | [+3] | |
Mar 18, 2026 | United States | Series B | 7712 | [+11] | |
Dec 01, 2025 | United States | Series B | 5730 | ||
Jun 20, 2024 | United States | Series A | 2601 | [+1] | |
Jan 12, 2024 | Canada | Series A | 9806 | [+5] |
IPOs and Publicly Listed companies in MPM BioImpact's Portfolio
2 of MPM BioImpact's portfolio companies have become public. Adlai Nortye got listed on the National Association of Securities Dealers Automated Quotations (NASDAQ), in Sep 2023 at marketcap of $57.5M and Idun Pharmaceuticals got listed on the Stockholm Stock Exchange (STO).Here are MPM BioImpact's portfolio companies that went public:
Company | IPO Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Sep 29, 2023 | Apr 16, 2026 | Post IPO | 4872 | |
Mar 26, 2021 | Jun 14, 2004 | Series B | 7728 |
Acquired companies in MPM BioImpact's Portfolio
3 companies from MPM BioImpact's portfolio have been acquired. The most recent acquisition was Radius Health in Jan 2026 by B-FLEXION for $*****.Here are MPM BioImpact's portfolio companies that got acquired most recently:
Company | Acquisition Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Jan 12, 2026 | Sep 17, 2007 | Series C | 3239 | |
Jun 01, 2023 | Jan 12, 2024 | Series A | 3045 | |
Apr 16, 2008 | Jan 28, 2002 | Series B | 6505 |
Team profile of MPM BioImpact
MPM BioImpact has a team of 25 members including 14 Partners and 3 Principals located in United States and Germany. MPM BioImpact's team sits on the board of 1 company.Here is a list of top team members in MPM BioImpact:
Name | Designation | Location | Board Memberships | Contact Details |
|---|---|---|---|---|
Partner | Boston | - | - | |
Partner | Boston | - | ||
Partner | Munich | - | - | |
Partner | Boston | - | - | |
Partner | Newtown | - | ||
Partner | - | - | ||
Partner | Brookline | - | - | |
Partner | Boston | - | - | |
Partner | Cambridge | - | - | |
Partner | Redwood City | - | - |
Co-investors of MPM BioImpact
Over the past 25 years, 89 investors have co-invested in MPM BioImpact's portfolio companies. This includes only funds.
- Invested before MPM BioImpact: Wellcome, Healthcare Ventures and 33 others have invested in rounds before MPM BioImpact. There is 1 company where Wellcome has invested before MPM BioImpact and 1 company where Healthcare Ventures has invested before MPM BioImpact.
- Top Co-investors of MPM BioImpact: 41 investors entered a company along with MPM BioImpact. These include investors like Novo Holdings (1 company).
- Invested after MPM BioImpact: A total of 13 investors have invested in MPM BioImpact's portfolio after their investments. Top Investors include Webster Equity Partners (1 company), Brookside Capital (1 company) and Saints Capital (1 company).
Recent News related to MPM BioImpact
•
•
Briggs Morrison's Crossbow Unveils $77M Series B for T Cell EngagersEndpoints•Mar 18, 2026•Crossbow, Arkin, MPM BioImpact, LifeLink Ventures and 11 others
•
•
Protego gets $130M for AL amyloidosis drug from leaders behind VyndaqelEndpoints•Dec 01, 2025•Protegobio, Brown Rudnick, Omega Funds, Novartis Venture Fund and 8 others
•
MPM Bioimpact LLC Acquires New Position in Vera TherapeuticsMarketBeat•May 16, 2025•Vera Therapeutics, MPM BioImpact
•
•
MPM Bioimpact LLC Invests $4.23 Million in Axsome TherapeuticsMarketBeat•May 16, 2025•Axsome Therapeutics, MPM BioImpact
•
MPM Bioimpact LLC Acquires 4,285,365 Veru Inc. SharesMarketBeat•May 16, 2025•Veru Healthcare, MPM BioImpact
•
MPM Bioimpact LLC Invests $8.12 Million in United TherapeuticsMarketBeat•May 16, 2025•MPM BioImpact, United Therapeutics
•
Olema Pharmaceuticals, Inc. (OLMA) Shares Acquired by MPM Bioimpact LLCMarketBeat•May 16, 2025•Olema Oncology, MPM BioImpact
